Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

K Vrzalikova; J Skarda; J Ehrmann; Paul Murray; E Fridman; J Kopolovic; P Knizetova; M Hajduch; J Klein; V Kolek; L Radova; Z Kolar

doi:10.1007/s00432-008-0361-y

Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

K Vrzalikova, J Skarda, J Ehrmann, Paul Murray, E Fridman, J Kopolovic, P Knizetova, M Hajduch, J Klein, V Kolek, L Radova, Z Kolar

Cancer and Genomic Sciences

Research output: Contribution to journal › Article

86 Citations (Scopus)

Abstract

Purpose Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

Original language	English
Pages (from-to)	1037-1042
Number of pages	6
Journal	Journal of Cancer Research and Clinical Oncology
Volume	134
Issue number	9
DOIs	https://doi.org/10.1007/s00432-008-0361-y
Publication status	Published - 1 Sept 2008

Keywords

polycomb genes
non-small cell lung cancer
tissue microarray
Bmi-1 oncogene

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00432-008-0361-y

Cite this

@article{c03d69c385754188a207e2b4ac09ae67,

title = "Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study",

abstract = "Purpose Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.",

keywords = "polycomb genes, non-small cell lung cancer, tissue microarray, Bmi-1 oncogene",

author = "K Vrzalikova and J Skarda and J Ehrmann and Paul Murray and E Fridman and J Kopolovic and P Knizetova and M Hajduch and J Klein and V Kolek and L Radova and Z Kolar",

year = "2008",

month = sep,

day = "1",

doi = "10.1007/s00432-008-0361-y",

language = "English",

volume = "134",

pages = "1037--1042",

journal = "Journal of Cancer Research and Clinical Oncology",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

AU - Vrzalikova, K

AU - Skarda, J

AU - Ehrmann, J

AU - Murray, Paul

AU - Fridman, E

AU - Kopolovic, J

AU - Knizetova, P

AU - Hajduch, M

AU - Klein, J

AU - Kolek, V

AU - Radova, L

AU - Kolar, Z

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

AB - Purpose Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

KW - polycomb genes

KW - non-small cell lung cancer

KW - tissue microarray

KW - Bmi-1 oncogene

U2 - 10.1007/s00432-008-0361-y

DO - 10.1007/s00432-008-0361-y

M3 - Article

C2 - 18264721

VL - 134

SP - 1037

EP - 1042

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 9

ER -

Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this